Welcome!

News Feed Item

Lombard Medical Technologies PLC: Pre-Close Trading and Strategic Update

LONDON, UK -- (Marketwired) -- 01/08/14 --


                   Lombard Medical Technologies PLC
                 ("Lombard Medical" or "the Company")

                Pre-Close Trading and Strategic Update

         Global AorfixTM growth; US rollout progressing well
  Intention to pursue a US IPO and NASDAQ listing of ordinary shares

London, UK and Irvine, CA, 8 January, 2014 - Lombard Medical
Technologies PLC (AIM: LMT), the specialist medical device company
focused on Endovascular Aortic Repair ("EVAR") of abdominal aortic
aneurysms ("AAAs"), announced today a pre-close trading update for the
financial year ended 31 December 2013 as well as a strategic update.
All figures are unaudited.

Trading Update

AorfixTM commercial revenue grew 25% to GBP3.9m with revenue from the
main EU markets growing 9%. Revenue from the Rest of World ("ROW")
markets grew 28% and the US contributed to fourth quarter Aorfix
commercial revenue growth of 38% following formal launch in November.
In Europe, the Company experienced strong demand and revenue growth in
Germany and Spain. Following consolidation of EVAR centers in the UK,
which negatively impacted UK revenue in the first half of 2013, second
half 2013 Aorfix revenue in the UK recovered and was flat compared to
the same period the previous year. Total Company revenue grew by 14% to
GBP4.5m, reflecting a decline in revenue of the recently divested OEM
business in Scotland which fell by 27% compared to last year. As
previously announced, this business was divested on 20 December 2013.

Aorfix was approved by the United States Food and Drug Administration
("US FDA") in February 2013 with a unique label indication for the
treatment of patients with angulations at the neck of the aneurysm up
to and including 90 degrees. The product was formally launched in the
US, the largest EVAR market, at the 40th Annual VEITH Symposium, in New
York in November. While Aorfix is still in the initial phase of the US
launch, the product rollout is progressing well, with the number of US
physicians trained to use the device standing at 244 at the year end.
As previously disclosed, the Company's 20-person sales team is
targeting around 300 high volume EVAR centers that perform more than
half of the EVAR procedures in the US.

In Japan, the Company now anticipates regulatory approval for Aorfix
during 2014. Our exclusive Japanese marketing partner, Medico's
Hirata, remains in dialogue with the Pharmaceuticals and Medical
Devices Agency (PMDA) to achieve this. Medico's Hirata is a leading
supplier of medical device products in Japan, with the sales
infrastructure to realize the potential of Aorfix in this growing
market, which in 2013 was estimated to account for approximately $140m
or 10% of the global EVAR market.

As previously announced, the Company is expanding its manufacturing
facility in Didcot, Oxfordshire, to support increasing global demand
for Aorfix. The expansion, which involves the construction of a new
cleanroom and materials handling space, will add around 10,000 sq. ft.
to the existing facility. The expansion project is expected to be
completed by the end of the first quarter of 2014.

The global AAA market for EVAR devices is estimated to be approximately
$1.4bn. The US market is estimated to be worth around half of the
global market and is expected to grow at a compound annual growth rate
in excess of 7% over the next 5 years, driven largely by the growth of
the ageing population and patient screening programs. In addition,
introduction of new technologies such as Aorfix, which allow more
patients to received endovascular treatment of AAA disease, could
potentially further expand the market.

The Company closed 2013 with cash of GBP24.8m and debt of GBP1.5m on its
balance sheet.

NASDAQ IPO

As announced today in a separate press release, the Company intends to
submit a registration statement to the US Securities and Exchange
Commission ("SEC") relating to a proposed US initial public offering of
ordinary shares and a listing on NASDAQ ("NASDAQ IPO").

To facilitate the NASDAQ IPO, a new Cayman Islands holding company will
be created and existing shares in Lombard Medical will be exchanged for
new shares in that holding company ("Share Exchange")

Commencement of the initial public offering is conditional upon
completion of the SEC review process with respect to the registration
statement and is subject to market conditions and other
considerations. In connection with the NASDAQ IPO, Lombard Medical
will also delist its ordinary shares from AIM, a market of the London
Stock Exchange.

In the Share Exchange, existing shareholders will receive shares in the
new Cayman Islands holding company in exchange for the shares they hold
in Lombard Medical. These new shares will not be admitted to trading on
AIM. Shareholders will need to consider their ability to hold and trade
NASDAQ listed shares following the Share Exchange and the AIM
delisting. Full details of the proposals will be set out in a circular
to shareholders in due course.

Lombard Medical intends to use proceeds from the NASDAQ IPO to
accelerate its commercialization strategy for Aorfix in the US with a
particular focus on continuing to expand its direct sales force to
accelerate penetration of the US AAA market. The Company will also
continue to invest in developing new products to treat complex vascular
disease, including a stent graft to treat aneurysms in the thoracic
aorta.

This press release does not constitute an offer of any securities for
sale.

                               -Ends-


For further information:

Lombard Medical Technologies PLC              Tel: +44 (0)1235 750 800
Simon Hubbert, Chief Executive Officer
Ian Ardill, Chief Financial Officer

Canaccord Genuity Limited                     Tel: +44 (0)20 7523 8000
Lucy Tilley / Tim Redfern /
Henry Fitzgerald O'Connor / Dr Julian Feneley

FTI Consulting (UK)                           Tel: +44 (0)20 7831 3113
Simon Conway / Stephanie Cuthbert /
Victoria Foster Mitchell

Allen & Caron (US)                            Tel: +1 (949) 474 4300
Matt Clawson


About Abdominal Aortic Aneurysms

AAAs are a balloon-like enlargement of the aorta which, if left
untreated, may rupture and cause death. Approximately 4.5 million
people are living with AAAs in the developed world and each year over
500,000 new cases are diagnosed. In the US, aortic aneurysm disease is
among the leading causes of death and it is estimated that 1.7 million
people over the age of 55 have an abdominal aortic aneurysm.

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT) is a medical device company
focused on device solutions for the $1.4 billion per annum abdominal
aortic aneurysm ("AAA") repair market. The Company's lead product,
Aorfix, is an endovascular stent graft which has been specifically
designed to solve the problems that exist in treating complex tortuous
anatomy, which is often present in advanced AAA disease. Aorfix is the
only stent graft approved for AAA neck angulations of up to 90 degrees
and is currently being commercialized worldwide. Aorfix is the first
AAA stent graft not of US origin to gain US FDA approval. The Company
is headquartered in Oxfordshire, England with US operations in Irvine,
CA.

Further background on the Company can be found at
www.lombardmedical.com.

FORWARD-LOOKING STATEMENTS

This announcement may contain forward-looking statements that reflect
the Company's current expectations regarding future events, including
the commercialization and regulatory clearance of the Company's
products, the Group's liquidity and results of operations, as well as
the Group's future capital raising activities. Forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of
factors, including the success of the Company's research and
development and commercialization strategies, the uncertainties related
to the regulatory process and the acceptance of the Company's products
by hospitals and other medical professionals.



                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
SYS-CON Events announced today that Niagara Networks will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management solutions, helping companies worldwide activate their data to drive more value and business insight and to transform moder...
SYS-CON Events announced today that eCube Systems, a leading provider of middleware modernization, integration, and management solutions, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. eCube Systems offers a family of middleware evolution products and services that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the protocols that communicate data and the emerging data analy...
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
We’ve been doing it for years, decades for some. How many websites have you created accounts on? Your bank, your credit card companies, social media sites, hotels and travel sites, online shopping sites, and that’s just the start. We do it often without even thinking about it, quickly entering our personal information, our data, in a plethora of systems. Sometimes we’re not even aware of the information we are providing. It could be very personal information (think of the security questions you ...
Digital innovation is the next big wave of business transformation based on digital technologies of which IoT and Big Data are key components, For example: Business boundary innovation is a challenge to excavate third-party business value using IoT and BigData, like Nest Business structure innovation may propose re-building business structure from scratch, as Uber does in the taxicab industry The social model innovation is also a big challenge to the new social architecture with the design fr...
Is your aging software platform suffering from technical debt while the market changes and demands new solutions at a faster clip? It’s a bold move, but you might consider walking away from your core platform and starting fresh. ReadyTalk did exactly that. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue and over a decade of audio conferencing product development to start an innovati...
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of So...
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at EMC, will introduce a methodology for capturing, enriching and sharing data (and analytics) across the organizati...
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. Big Data at Cloud Expo - to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is...